Proteostasis scores deal with CF Foundation; Silence could benefit from partner's Pfizer pact;

 @FierceBiotech: Roche abandons potential blockbuster cholesterol drug, bringing negative attention to similar drugs. News | Follow @FierceBiotech

 @RyanMFierce: Report says that a pharma startup operating in the offices of Lilly's VC unit raised $4.6M. Story | Follow @RyanMFierce

 @MarkHFierce: Folks, we're still taking nominations for the 15 fiercest private device developers. Make them here: Survey | Follow @MarkHFierce

> Cambridge, MA-based biotech startup Proteostasis has landed a research deal with the Cystic Fibrosis Foundation to hunt for small molecule drugs that could treat cystic fibrosis patients with the most common mutation that causes the genetic disease. Release

> RNAi developer Silence Therapeutics could gain from partner Quark Pharmaceuticals' extended pact with drug giant Pfizer ($PFE) to develop a treatment for open-angle glaucoma. Item

> The ALS Therapy Development Institute in Cambridge, MA, has struck a partnership deal with Regenesance to research a potential treatment for amyotrophic lateral sclerosis, known commonly as Lou Gehrig's disease. Release

Pharma News

 @FiercePharma: Pharma's biggest companies saw aggregate profits rise 12.8% on a slight uptick in sales last year, Pharmabiz finds. Report | Follow @FiercePharma

> Truvada up for FDA debate as HIV preventive. More

> Congress drags Big Pharma into Obamacare negotiation probe. Article

> Pharma continues parachute-building for patent cliff. Story

> Bayer slams Indian government, Cipla on Nexavar copies. Report

Medical Devices News

@FierceMedDev: Maria Sainz Joins CardioKinetix as President, CEO. Release | Follow @FierceMedDev

> OrthoSensor gains $15M to fuel knee implant commercialization. More

> Hope runs high that FDA user fee bill will escape congressional acrimony. Story

> Stereotaxis raises cash to shore up finances. Article

> Boston Scientific gains FDA sign-off for 3 new pacemakers. News

Biotech IT News

> Medidata snags biz from rival Oracle in record Q1. News

> Investors pour $50.8M into genomics standout Oxford Nanopore. News

> Startup tries Apple-like strategy in genomics field. Item

> Software provider to Merck taps IBM cloud to fight fake drugs. Article

> A case for 'open source' clinical trial data (locked behind a pay wall). More

> Genomics tops chart of social media buzz in biotech IT. Report

And Finally… Harvard scientists rigged bad fat with good fat properties in research that could shed light on new obesity treatments. Report

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.